| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |